A Study of Subcutaneous Gefurulimab Using Prefilled Syringe Versus Autoinjector in Healthy Adult Participants

• Status: COMPLETED
• Trial end date: 2024-09-28

Summary

This study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, immunogenicity, and device performance of gefurulimab.

• Phase: PHASE1

Details

• Lead Sponsor: Alexion Pharmaceuticals, Inc.
• Collaborator: Parexel